The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.50
Bid: 43.00
Ask: 44.40
Change: -3.30 (-7.02%)
Spread: 1.40 (3.256%)
Open: 44.60
High: 45.30
Low: 44.50
Prev. Close: 43.70
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Positive Opinion from the EMA on BMK08

10 Sep 2020 09:15

RNS Number : 6196Y
Benchmark Holdings PLC
10 September 2020
 

10 September 2020

 

Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014.

 

Benchmark Holdings plc

 

Important milestone reached towards commercialisation of BMK08 & CleanTreat®

Positive Opinion from the European Medicine Agency on the safety of BMK08

 

Benchmark, the aquaculture biotechnology business, is pleased to announce that on 10 September 2020 the Committee for Medicinal Products for Veterinary Use ("CVMP"), a committee of the European Medicine Agency, adopted an opinion recommending the inclusion of BMK08's active pharmaceutical ingredient in fin fish as an allowed substance regarding maximum residue limits in foodstuffs of animal origin (the "MRL opinion").

 

The MRL opinion is an important step towards the launch of BMK08 together with the Company's water purification system CleanTreat® in Q2 CY 2021. The MRL opinion is without prejudice to the European Commission's decision and ratification into EU law, which represents the next milestone for BMK08 together with CleanTreat®, and is a condition for obtaining Marketing Authorisation (MA) in Norway.

 

Trond Wiliksen, CEO commented:

 

"The MRL opinion is a significant stepping stone towards the launch of our novel sea lice treatment BMK08, together with CleanTreat® which purifies the treatment water. The positive opinion of the European Medicine Agency's experts in medicine safety is a critical step in a 10-year data collection and assessment process which ensures that the medicine is safe to use and safe for consumers."

 

"I congratulate our teams for getting us to this point and we look forward to making further progress towards a launch in Q2 CY 2021."

 

Enquiries

 

For further information, please contact:

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

MHP Communications

 

Tel: 020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver benchmark@mphc.com

 

 

About Benchmark 

Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGIGDCUBBDGGG
Date   Source Headline
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp
6th Nov 201712:20 pmRNSReplacement: Directorate Change
6th Nov 20177:00 amRNSDirectorate Change
30th Oct 20177:00 amRNSLand-based Broodstock Facility Reaches Milestone
17th Oct 20177:00 amRNSNew Vaccine Facility Delivers First Production
10th Oct 20172:41 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSBlock Listing Six Monthly Return
8th Sep 20177:00 amRNSTrading Update
22nd Aug 20177:00 amRNSRenewal of Sales and Marketing Agreement
16th Aug 20177:00 amRNSLaunch of breakthrough purification system
28th Jul 20172:57 pmRNSDirector leave of absence
27th Jun 20177:02 amRNSHalf-year Report
19th Jun 20173:00 pmRNSNotice of Results
25th May 20177:00 amRNSTrading Update and Notice of Results
2nd May 20177:00 amRNSTotal Voting Rights
26th Apr 201710:54 amRNSDirector Dealings
3rd Apr 20174:32 pmRNSBlock Listing Six Monthly Return
9th Mar 20178:44 amRNSDirector Share Options and Issue of Shares
7th Mar 201710:39 amRNSResult of AGM
7th Mar 20178:00 amRNSContract Win
2nd Mar 20173:34 pmRNSHolding(s) in Company
1st Mar 20172:09 pmRNSHolding(s) in Company
23rd Feb 20177:00 amRNSHolding(s) in Company
22nd Feb 20174:35 pmRNSHolding(s) in Company
16th Feb 20177:45 amRNSDirector Dealings
24th Jan 20177:00 amRNSFinal Results
3rd Jan 20177:00 amRNSTotal Voting Rights
1st Dec 20167:00 amRNSDirector/PDMR Shareholding
29th Nov 20167:00 amRNSCapital Markets Day
25th Nov 20167:00 amRNSAppointment of Non-Executive Director
23rd Nov 20164:52 pmRNSHolding(s) in Company
26th Oct 20167:00 amRNSTrading Statement
12th Oct 20167:00 amRNSBlock Admission Application
10th Oct 201612:02 pmRNSBlock listing Interim Review
31st Aug 20167:00 amRNSBenchmark secures innovative new equine vaccine
12th Aug 201612:41 pmRNSHolding(s) in Company
11th Aug 20167:00 amRNSAcq of South American shrimp breeding programme
10th Aug 20163:37 pmRNSHolding(s) in Company
10th Aug 20161:40 pmRNSHolding(s) in Company
10th Aug 20161:33 pmRNSHolding(s) in Company
10th Aug 20161:29 pmRNSHolding(s) in Company
9th Aug 20163:26 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.